Y. Nakanishi (Fukuoka, Japan), E. Quoix (Strasbourg, France)
Late-breaking abstract: Relationship of aquaporin 1, 3 and 5 expression in lung cancer cells to cellular differentiation, invasive growth and metastasis potential M. Shimasaki, Y. Machida, Y. Takahara, H. Toga, Y. Ueda (Kahoku-gun, Japan)
| |
A phase III randomised trial assessing the activity of first-line ifosfamide-gemcitabine (IG), a non-platinum chemotherapy (CT), in patients with advanced non-small cell lung cancer (NSCLC) T. Berghmans, J. J. Lafitte, M. Paesmans, A. P. Meert, A. Scherpereel, N. Leclercq, J. P. Sculier (Brussels, Belgium; Lille, France)
| |
Gemcitabine sensitizes lung cancer cells to Fas /Fas ligand system-mediated killing L. Siena, E. Pace, M. Ferraro, C. Di Sano, M. Melis, M. Profita, M. Gjomarkaj (Palermo, Italy)
| |
Non-small cell lung cancer treatment by inhalation of Erbitux and gemcitabine in murine model Y. Schwarz, O. Merimsky, A. Starr (Tel Aviv, Israel)
| |
Use of erlotinib in management of advanced non-small cell lung cancer (NSCLC): The Czech Republic experience with the treatment of a non-selected population of 1735 patients (pts) J. Skrickova, M. Pesek, P. Zatloukal, V. Kolek, F. Salajka, L. Koubkova, J. Krejci, M. Tomiskova, G. Ivona, M. Hrnciarik (Brno, Plzen, Praha, Olomouc, Hradec Kralove, Czech Republic)
| |
Gefitinib selectively targets non-small cell lung cancer cells through inhibition of Forkhead box M1 N. Xu, C. Bai (Shanghai, China)
| |
Carboplatin-paclitaxel alone or with bevacizumab in stage III-IV lung adenocarcinoma G. Hardavella, S. Nikolakopoulou, I. Kostara, G. Hillas, M. Alchanatis, F. Vlastos (Athens, Greece)
| |
Intraoperative photodinamic therapy as a part of combined radical treatment for stage III NSCLC A. Akopov, A. Rusanov, G. Papayan, V. Molodtcova, M. Urtenova, I. Chistiakov, N. Kazakov (Saint-Petersburg, Russian Federation)
| |